Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients: a study from the Hellenic Group of Sarcoma and Rare Cancers
Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of a...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
31 January 2023
|
| In: |
Journal of Clinical Medicine
Year: 2023, Jahrgang: 12, Heft: 3, Pages: 1-10 |
| ISSN: | 2077-0383 |
| DOI: | 10.3390/jcm12031119 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcm12031119 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2077-0383/12/3/1119 
|
| Verfasserangaben: | Stefania Kokkali, Anastasios Kyriazoglou, Elpida Mangou, Panagiota Economopoulou, Michail Panousieris, Amanda Psyrri, Alexandros Ardavanis, Nikolaos Vassos and Ioannis Boukovinas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 190299437X | ||
| 003 | DE-627 | ||
| 005 | 20241205173209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240919s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12031119 |2 doi | |
| 035 | |a (DE-627)190299437X | ||
| 035 | |a (DE-599)KXP190299437X | ||
| 035 | |a (OCoLC)1475312588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kokkali, Stefania |e VerfasserIn |0 (DE-588)1342447573 |0 (DE-627)1902995929 |4 aut | |
| 245 | 1 | 0 | |a Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients |b a study from the Hellenic Group of Sarcoma and Rare Cancers |c Stefania Kokkali, Anastasios Kyriazoglou, Elpida Mangou, Panagiota Economopoulou, Michail Panousieris, Amanda Psyrri, Alexandros Ardavanis, Nikolaos Vassos and Ioannis Boukovinas |
| 264 | 1 | |c 31 January 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.09.2024 | ||
| 520 | |a Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17-83). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms. | ||
| 650 | 4 | |a bone sarcoma | |
| 650 | 4 | |a cabozantinib | |
| 650 | 4 | |a Ewing sarcoma | |
| 650 | 4 | |a osteosarcoma | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 700 | 1 | |a Kyriazoglou, Anastasios |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mangou, Elpida |e VerfasserIn |4 aut | |
| 700 | 1 | |a Economopoulou, Panagiota |e VerfasserIn |4 aut | |
| 700 | 1 | |a Panousieris, Michail |e VerfasserIn |4 aut | |
| 700 | 1 | |a Psyrri, Amanda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ardavanis, Alexandros |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vassos, Nikolaos |d 1983- |e VerfasserIn |0 (DE-588)1054092133 |0 (DE-627)791023923 |0 (DE-576)40998485X |4 aut | |
| 700 | 1 | |a Boukovinas, Ioannis |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Clinical Medicine |d Basel : MDPI, 2012 |g 12(2023), 3, Artikel-ID 1119, Seite 1-10 |h Online-Ressource |w (DE-627)718632478 |w (DE-600)2662592-1 |w (DE-576)365782718 |x 2077-0383 |7 nnas |a Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients a study from the Hellenic Group of Sarcoma and Rare Cancers |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:3 |g elocationid:1119 |g pages:1-10 |g extent:10 |a Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients a study from the Hellenic Group of Sarcoma and Rare Cancers |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm12031119 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/12/3/1119 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240919 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1054092133 |a Vassos, Nikolaos |m 1054092133:Vassos, Nikolaos |d 60000 |d 61800 |e 60000PV1054092133 |e 61800PV1054092133 |k 0/60000/ |k 1/60000/61800/ |p 8 | ||
| 999 | |a KXP-PPN190299437X |e 4581676444 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 19.09.2024"],"recId":"190299437X","name":{"displayForm":["Stefania Kokkali, Anastasios Kyriazoglou, Elpida Mangou, Panagiota Economopoulou, Michail Panousieris, Amanda Psyrri, Alexandros Ardavanis, Nikolaos Vassos and Ioannis Boukovinas"]},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"31 January 2023"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.3390/jcm12031119"],"eki":["190299437X"]},"language":["eng"],"relHost":[{"origin":[{"publisher":"MDPI","dateIssuedKey":"2012","dateIssuedDisp":"2012-","publisherPlace":"Basel"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"zdb":["2662592-1"],"issn":["2077-0383"],"eki":["718632478"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"open access journal","title":"Journal of Clinical Medicine","title_sort":"Journal of Clinical Medicine"}],"part":{"extent":"10","year":"2023","issue":"3","volume":"12","text":"12(2023), 3, Artikel-ID 1119, Seite 1-10","pages":"1-10"},"disp":"Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients a study from the Hellenic Group of Sarcoma and Rare CancersJournal of Clinical Medicine","note":["Gesehen am 12.06.20"],"pubHistory":["1.2012 -"],"recId":"718632478"}],"person":[{"given":"Stefania","display":"Kokkali, Stefania","family":"Kokkali","role":"aut"},{"display":"Kyriazoglou, Anastasios","family":"Kyriazoglou","given":"Anastasios","role":"aut"},{"role":"aut","given":"Elpida","display":"Mangou, Elpida","family":"Mangou"},{"role":"aut","display":"Economopoulou, Panagiota","family":"Economopoulou","given":"Panagiota"},{"role":"aut","display":"Panousieris, Michail","family":"Panousieris","given":"Michail"},{"role":"aut","family":"Psyrri","display":"Psyrri, Amanda","given":"Amanda"},{"role":"aut","display":"Ardavanis, Alexandros","family":"Ardavanis","given":"Alexandros"},{"given":"Nikolaos","display":"Vassos, Nikolaos","family":"Vassos","role":"aut"},{"role":"aut","given":"Ioannis","display":"Boukovinas, Ioannis","family":"Boukovinas"}],"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"title":[{"title_sort":"Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients","title":"Real-world data on cabozantinib in advanced osteosarcoma and ewing sarcoma patients","subtitle":"a study from the Hellenic Group of Sarcoma and Rare Cancers"}]} | ||
| SRT | |a KOKKALISTEREALWORLDD3120 | ||